Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Feb 15;12(3):ofaf094.
doi: 10.1093/ofid/ofaf094. eCollection 2025 Mar.

Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic

Geoffroy Liegeon  1 , Christopher Kaperak  1 , Eleanor E Friedman  1 , Paul Djuricich  2 , Alicia Dawdani  1 , Kane Stafford  2 , Sophie Plotkin  1 , Jessica Schmitt  1 , Aniruddha Hazra  1 , Katerina A Christopoulos  3 , John A Schneider  1 , Moira C McNulty  1
Affiliations
Clinical Trial

Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic

Geoffroy Liegeon et al. Open Forum Infect Dis. .

Abstract

We describe referrals and uptake of long-acting injectable cabotegravir/rilpivirine at an academic clinic in Chicago. In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.

Keywords: cabotegravir; injectable; long-acting; people with HIV; rilpivirine.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. G. L. has participated in advisory boards for ViiV Healthcare. M. C. M. has served on an advisory board for Gilead Sciences. K. A. C. has been a medical advisory board member for Gilead Sciences and a workshop participant for Janssen. K. S. joined ViiV Healthcare in 2024 after the completion of this research. All other authors report no potential conflicts.

Figures

Figure 1.
Figure 1.
Flowchart of PWH at the University of Chicago, including those referred and initiating LAI-CAB/RPV. Abbreviations: LAI-CAB/RPV, long-acting injectable cabotegravir/rilpivirine; PWH, people with HIV.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention . Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2022. HIV Surveillance Supplemental Report 2023; 28(4). Available at: https://stacks.cdc.gov/view/cdc/156511. Accessed 27 January 2025.
    1. Garris C, Desai R, Chang R, et al. 1024: real-world adherence and persistence with long-acting cabotegravir plus rilpivirine (CAB + RPV LA) compared to oral antiretroviral therapy (ART) among people with HIV (PWH) in the US: the ABOVE study. Open Forum Infect Dis 2023; 10(suppl 2):ofad500.055.
    1. Clemenzi-Allen A, Geng E, Christopoulos K, et al. Degree of housing instability shows independent “dose-response” with virologic suppression rates among people living with human immunodeficiency virus. Open Forum Infect Dis 2018; 5:ofy035. - PMC - PubMed
    1. Dandachi D, May SB, Davila JA, et al. The association of unmet needs with subsequent retention in care and HIV suppression among hospitalized patients with HIV who are out of care. J Acquir Immune Defic Syndr 2019; 80:64–72. - PMC - PubMed
    1. Lesko CR, Hutton HE, Fojo AT, Shen NM, Moore RD, Chander G. Depression and HIV viral nonsuppression among people engaged in HIV care in an urban clinic, 2014–2019. AIDS 2021; 35:2017–24. - PMC - PubMed

Publication types